Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Altis Labs has unveiled Nota, a groundbreaking clinical information platform designed to expedite therapeutic research and development. By harnessing the power of AI, Nota can forecast patient outcomes based on imaging data, allowing sponsors to efficiently prioritize their most promising therapies. This innovative platform empowers researchers to effectively utilize clinical trial imaging data, gain access to predictive imaging biomarkers, and enhance R&D efforts on a larger scale. With Altis’ cloud-based software, which employs advanced deep learning techniques, biopharma companies can integrate detailed outcome predictions at the image, patient, and cohort levels, ultimately refining clinical trial design and boosting confidence in anticipating clinical endpoints. The insights generated by Nota have the potential to drastically shorten development timelines, reduce drug development expenses, and increase the chances of success across various therapeutic areas, paving the way for a new era in clinical research. As the demand for efficient drug development continues to rise, Nota stands out as a vital tool for the biopharmaceutical industry.
Description
Introducing a versatile API designed to seamlessly integrate with your diabetes management system, offering tailored therapeutic education and enhanced insights into blood glucose level fluctuations. This solution enables real-time risk predictions, fostering greater personalization and improved system regulation, while adeptly managing complex living scenarios characterized by rapid glucose variations. With advancements in telemedicine and retrospective analysis, patients receive robust decision-support tools. Currently, Hillo is developing the next iterations of its AI technology, which includes a therapeutic recommendation system aimed at preventing hypoglycemia and hyperglycemia, anticipated to achieve CE mark class IIB by 2020. Additionally, a new generation of the artificial pancreas is projected for release in 2021, addressing key limitations of existing systems through ultra-personalization driven by machine learning. This innovative approach marks the introduction of the first self-learning artificial intelligence capable of predicting blood glucose levels, aiming to secure a CE mark as a medical device, thereby transforming diabetes management for users. In essence, Hillo's advancements could significantly enhance the quality of life for individuals managing diabetes.
API Access
Has API
No
API Access
Has API
Yes
Integrations
No details available.
Integrations
No details available.
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Pricing Details
No price information available.
Free Trial
Yes
Free Version
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Customer Support
Business Hours
No
Live Rep (24/7)
No
Online Support
Yes
Customer Support
Business Hours
No
Live Rep (24/7)
No
Online Support
Yes
Types of Training
Training Docs
No
Webinars
No
Live Training (Online)
No
In Person
No
Types of Training
Training Docs
Yes
Webinars
No
Live Training (Online)
No
In Person
Yes
Vendor Details
Company Name
Altis Labs
Founded
2019
Country
Canada
Website
www.altislabs.com/news/altis-labs-announces-launch-of-nota-a-clinical-information-platform-to-accelerate-therapeutic-r-d
Vendor Details
Company Name
Hillo
Country
France
Website
www.hillo.ai/